DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION

Exicure, Inc.

NasdaqCM:XCUR Stock Report

Market Cap: US$9.4m

  • Company Overview
  • Valuation
  • Future Growth
  • Past Performance
  • Financial Health
  • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

Exicure Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Jungsoo Kim

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureless than a year
Board average tenureless than a year

Recent management updates

Recent updates

Analysis Article • Aug 29

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Exicure, Inc. ( NASDAQ:XCUR ) shareholders won't be pleased to see that the share price has had a very rough month...
Seeking Alpha • Sep 26

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Early-stage biotech Exicure (NASDAQ:XCUR) on Monday announced a host of strategic actions, including a workforce reduction of about 66% and a halt to its research and development activities and its pre-clinical studies. The company estimated that it will incur total expenses relating to the restructuring of about $0.5M, adding that it expects the strategic actions to extend its cash runway into Q2 2023. XCUR said it would explore divestiture options for its SCN9A clinical program developing candidates for neuropathic pain, as results from a recent animal study did not meet "desired target engagement levels." In Monday's statement, XCUR also said it had entered into a private placement in public equity (PIPE) financing with existing investor CBI USA for anticipated gross proceeds of about $5.4M. CBI USA would also hold a controlling stake in XCUR equivalent to about 50.4% of the total voting power upon satisfaction of certain deal closing conditions. XCUR stock earlier closed +10.4% at $1.70.
Seeking Alpha • Aug 15

Exicure Q2 GAAP loss per share narrows, revenue up

Exicure press release (NASDAQ:XCUR): Q2 GAAP EPS of -$1.66 (vs. -$4.86 Y/Y). Revenue of $2.5M (vs. $0.1M Y/Y). Shares -9.05% AH.
Seeking Alpha • Jul 20

Exicure regains compliance with Nasdaq's minimum bid price requirement

Nasdaq has informed Exicure (NASDAQ:XCUR) that the biotechnology company has regained compliance with the stock exchange's $1.00 per share minimum bid price requirement. XCUR is now in compliance with all applicable listing standards, and the company's shares will continue to be listed and traded on the Nasdaq Capital Market. The shares closed at $1.72 on July 20. Source: Press Release
Seeking Alpha • Jun 29

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

Exicure (NASDAQ:XCUR) announces that following the implementation of a one-for-thirty reverse stock split, the company’s common stock will begin trading on a split-adjusted basis on Nasdaq effective open of Thursday, June 30, 2022. On December 30, 2021, Nasdaq notified the company that it no longer satisfied the minimum bid price requirement as the bid price for the stock had closed below $1.00 per share for the previous thirty consecutive business days. Stock dumps ~31%.
Analysis Article • Aug 25

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

CEO

Jungsoo Kim (53 yo)

less than a year
Tenure

Mr. Jungsoo Kim is CEO and President at Exicure, Inc since February 11, 2026 and is its Director since February 09, 2026. He serves as Chairman & CEO of AGEDB Technology Ltd. since May 27,2025.He holds a...


Leadership Team

NamePositionTenureCompensationOwnership
Jungsoo Kim
CEO, President & Directorless than a yearno datano data
Gyuyeob Lee
Interim CFO & Secretaryless than a yearno datano data
Young Ko
Chief Operating Officerless than a yearno datano data
Joshua Miller
Chief Accounting Officer3.3yrsno data0.0046%
$ 430.6
Devki Sukhtankar
Head of Preclinical Research & Translational Medicineless than a yearno datano data
Niña Caculitan
Head of Clinicalless than a yearno datano data
0.8yrs
Average Tenure
49.5yo
Average Age

Experienced Management: XCUR's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jungsoo Kim
CEO, President & Directorless than a yearno datano data
Dongho Lee
Independent Director3.1yrsUS$20.00kno data
Gyeung Cheon
Independent Directorless than a yearno datano data
Yoontae Han
Directorless than a yearno datano data
Eui Han
Independent Directorless than a yearno datano data
Jin Go
Directorless than a yearno datano data
0.5yrs
Average Tenure
53yo
Average Age

Experienced Board: XCUR's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/10 23:03
End of Day Share Price 2026/09/10 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Exicure, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Keay NakaeChardan Capital Markets, LLC
Yatin SunejaGuggenheim Securities, LLC

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide